Meizon has been granted both Orphan Drug Designation & Rare Pediatric Disease designation by the US FDA.
Meizon is developing a portfolio of patented biologically active molecules for preventing,
treating and potentially reversing the trajectory of brain disorders. DL33 is a therapeutic treatment for Dementia by replenishing deficient DL33 levels in the brain.
On November 5, Meizon Innovations announced that the U.S. FDA has granted its drug DL33 both Orphan Drug Designation and Rare Pediatric Disease Designation for Niemann-Pick disease type C. These designations recognise DL33's potential to address significant unmet needs. Unlike other treatments, Meizon's approach is rooted in scientific evidence aimed at proving DL33's effectiveness in treating dementia. Initial studies in mice have shown promise in reversing dementia effects, but further research is needed to meet FDA standards. Next steps include animal toxicology testing, followed by human safety testing in a Phase 1 study.
What is DL33?
To join our fight, as well as fund vital research for a cure, support the Australian NPC Disease Foundation in its goals of "Research. Cure. Persevere."
Ways to support NP-C in Australia:
Shop at our online NPC store
Fundraise your way! Check our free resources and inspo online.